. Author manuscript; available in PMC: 2022 Oct 31.

Published in final edited form as: Am J Gastroenterol. 2020 Mar;115(3):398–405. doi: 10.14309/ajg.0000000000000492

Table 3.

Baseline serum iron parameters in survivors and nonsurvivors based on 28-day mortality

Characteristic	Exploratory population (n = 200)	Replication population (n = 628)
Ferritin (ng/mL)	526 (219–1,147) vs 1,050 (594–2003)	723 (313–1,460) vs 1,033 (531–1,590)
Ferritin (ng/mL)	OR 1.001, 95% CI 1.000–1.001 P = 0.001	OR 1.000, 95% CI 1.000–1.000 P = 0.07
Transferrin (mg/dL)	102 (78–132) vs 74 (57–99)	126 (96–171) vs 96 (71–129)
Transferrin (mg/dL)	OR 0.98, 95% CI 0.97–0.99 P = 0.0001	OR 0.99, 95% CI 0.983–0.995 P = 0.0002
TSAT (%)	65 (36–83) vs 82 (53–95)	56 (33–81) vs 80 (41–91)
TSAT (%)	OR 1.02, 95% CI 1.01–1.04 P = 0.001	OR 1.02, 95% CI 1.01–1.03 P = 0.0001
Iron (μmol/L)	13.8 (9.3–18.6) vs 13.8 (11.4–17.4)	16.5 (11.4–22.9) vs 15.9 (11.9–22.5)
Iron (μmol/L)	OR 0.98, 95% CI 0.94–1.03 P = 0.53	OR 0.99, 95% CI 0.96–1.02 P = 0.51
Hepcidin (ng/mL)	7.2 (2.5–18.6) vs 17.6 (6.2–35.2)	12.4 (4.6–26) vs 12.3 (4.8–28.4)
Hepcidin (ng/mL)	OR 1.02, 95% CI 1.01–1.04 P = 0.007	OR 1.005, 95% CI 0.99–1.02 P = 0.50

Baseline serum parameters were available in 828 patients, who were randomly divided into the exploratory and replication subgroup. Data obtained from 28-day survivors vs nonsurvivors are shown as medians and interquartile ranges.

CI, confidence interval; OR, odds ratio; TSAT, transferrin saturation.